A new study suggests preexisting cardiovascular risk is not a significant factor in whether patients should continue or discontinue renin-angiotensin system inhibitors before noncardiac surgery.
of patients undergoing major noncardiac surgery found no difference in the postoperative risk for death or major complications in those who continued or discontinued treatment with renin-angiotensin system inhibitors prior to the procedure.
A new post hoc analysis of the randomized controlled trial found stratification of preoperative cardiovascular risk does not affect patient outcomes for the strategy, either.Researchers conducted a post hoc analysis of the multicenter STOP-or-NOT randomized clinical trial, which included patients at 40 hospitals in France between January 2018 and April 2023, with a 28-day postoperative follow-up. Participants included 2222 patients who had been treated with RASi agents for at least 3 months before undergoing major noncardiac surgery. Patients were randomly assigned to either continue taking their RASi until the day of surgery or discontinue the medication 48 hours before the procedure. Primary outcome measures were a composite of all-cause mortality and major postoperative complications. Secondary outcomes included major cardiovascular events and acute kidney injury. The researchers used the Revised Cardiac Risk Index , the American University of Beirut-HAS2 Cardiovascular Risk Index, and systolic blood pressure prior to randomization to assess cardiovascular risk.Using the RCRI, 592 patients were categorized as low risk, 1095 as intermediate-low risk, 418 as intermediate-high risk, and 117 as high risk. The American University of Beirut-HAS2 score categorized 1049 patients as low risk, 727 as intermediate-low risk, 333 as intermediate-high risk, and 113 as high risk. While the risk for postoperative complications and major cardiovascular events varied with a person’s score on the RCRI, continuing or discontinuing RASi was not associated with an increased risk for surgical complications.“This study found that preoperative cardiovascular risk did not affect patient outcomes with respect to the strategy of continuing vs discontinuing RASi before major noncardiac surgery, suggesting that the decision to continue or discontinue RASi should not be influenced by a patient’s preoperative cardiovascular risk assessment,” the researchers wrote.The study was led by Matthieu Legrand, MD, PhD, of the Department of Anesthesia and Perioperative Care at the University of California, San Francisco. It was published online on June 25 in The researchers acknowledged several limitations of the research, including how the sample size may have limited the ability to detect complications with small effects in subpopulations. The absence of systematic postoperative troponin measurements also reduced sensitivity in detecting myocardial injury.Several of the authors disclosed receiving grants from the National Institutes of Health, the Department of Defense, Edwards Lifesciences, Nordic Pharma, and others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our
Cardiovascular Risk CV Risk Factors Cardiovascular Risk Factors Cardiovascular Risk Management CV Risk Management Hypertension Surgery Postoperative Postoperative Complications Postoperative Complication Acute Pain Patient Safety Blood Pain Management Preoperative
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
No, the KETO-CTA Study Did Not Upend Causal Evidence on Atherosclerotic Cardiovascular DiseaseIs there really no link between high LDL-C and atherosclerosis in lean-mass hyperresponders on a keto diet? The data are nowhere close to supporting the authors' outsized claims, writes John Mandrola.
Read more »
Remission, Attaining CV Risk Targets Drops CVD Risk in LupusLong-term control of cardiovascular risk factors and sustained clinical remission help to mitigate the higher risk for atherosclerosis progression in patients with lupus.
Read more »
Cannabis Use Is Tied to a Substantially Higher Risk of Death From Cardiovascular DiseaseLearn about the link between cannabis use and death from cardiovascular disease, which could change the way we approach the drug in the future.
Read more »
Marijuana doubles your risk of cardiovascular death, worrying new study showsThough often seen as a wellness tool, cannabis use—even in edible form—is now tied to increased chances of a heart attack or stroke
Read more »
Should Cardiovascular Risk Equations Add Lp(a)?Adding Lp(a) to the PREVENT risk equations did not significantly improve risk prediction at the population level, but individuals may still benefit from knowing their levels.
Read more »
Meeting Target Serum Urate Level Cuts Cardiovascular Risk in GoutGout patients who met a target serum urate level of | 360 μmol/L (6 mg/dL) within 12 months of treatment cut their risk for major cardiovascular events vs patients who did not.
Read more »